Paul Stamets on science: what the evidence says · JRE #1385

What the evidence says 01 / RECORD

Stamets is citing a real, peer-reviewed study he co-authored: Stamets et al., "Extracts of Polypore Mushroom Mycelia Reduce Viruses in Honey Bees," Scientific Reports (2018). The paper reports that in an initial caged-bee lab trial, extracts of Fomes fomentarius (amadou) mycelium reduced deformed wing virus (DWV) levels more than 800-fold relative to controls (n=10), and in field trials, Ganoderma resinaceum (reishi) extract was associated with a 45,000-fold reduction in Lake Sinai virus (LSV) and a separate 79-fold reduction in DWV. These figures are accurately quoted from the paper's own reported results, based on qPCR-measured viral loads rather than direct measures of colony survival or bee health outcomes. The study was a single research group's trial with modest sample sizes and has not been independently replicated at the reported magnitudes by other labs; later independent studies on fungal extracts and honeybee health have tested different endpoints (e.g., bee lifespan, gut health) without reproducing these specific fold-reduction figures. The paper's competing-interests statement discloses that Paul Stamets holds patents on the use of fungal extracts for antiviral activity and honey bee health, and that co-author W.S. Sheppard received a research grant from Stamets' company, Fungi Perfecti LLC, to conduct the cage trials. The reported numbers are accurately stated, but the study is small, industry-linked, and not independently confirmed at that scale, so the results should be treated as preliminary rather than established evidence of practical antiviral efficacy in commercial beekeeping.